Multiple sclerosis (MS) is the commonest non‐traumatic disabling disease to affect young
adults. The incidence of MS is increasing worldwide, together with the socioeconomic …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Objective Gray matter (GM) atrophy occurs in all multiple sclerosis (MS) phenotypes. We
investigated whether there is a spatiotemporal pattern of GM atrophy that is associated with …

Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Objective: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active
relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In …

Overactivation of microglia is associated with most neurodegenerative diseases. In this
study we examined whether PET-measurable innate immune cell activation predicts multiple …

Background:'No evidence of disease activity'(NEDA), defined as absence of magnetic
resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and …

Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …